Create Free Account

By creating account you will get access to hot stocks & personalised emails

Proteomics Intl Labs Ltd

Healthcare AU PIQ

0.635AUD
-0.015(2.31%)

Last update at 2024-12-19T04:05:00Z

Day Range

0.610.66
LowHigh

52 Week Range

0.551.40
LowHigh

Fundamentals

  • Previous Close 0.65
  • Market Cap87.77M
  • Volume64025
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-6.11375M
  • Revenue TTM3.28M
  • Revenue Per Share TTM0.03
  • Gross Profit TTM 0.84M
  • Diluted EPS TTM-0.05

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -6.23431M -4.97296M -2.85966M -1.74377M -2.08027M
Minority interest - - - - -
Net income -6.23431M -4.97296M -2.85966M -1.74377M -2.10733M
Selling general administrative 5.11M 4.36M 2.87M 2.24M 2.16M
Selling and marketing expenses - 0.12M 0.06M 0.08M 0.23M
Gross profit -1.61511M -0.56862M 0.50M 0.58M 1.47M
Reconciled depreciation 0.53M 0.42M 0.37M 0.36M 0.19M
Ebit -8.82815M -4.97251M -2.85956M -1.73486M -2.05322M
Ebitda -8.29862M -4.55565M -2.48704M -1.37116M -1.86492M
Depreciation and amortization 0.53M 0.42M 0.37M 0.36M 0.19M
Non operating income net other - - - - -
Operating income -6.36560M -4.97728M -3.08268M -1.99821M -2.05322M
Other operating expenses 4.86M 4.29M 3.98M 2.80M 4.54M
Interest expense - 0.00045M 0.00010M 0.00891M 0.03M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.14M 0.00544M 0.01M 0.02M 0.28M
Net interest income 0.14M 0.00275M 0.00805M 0.01M 0.02M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.14836M 1.94M 1.64M 1.58M 0.03M
Total revenue 0.73M 1.49M 1.31M 1.42M 1.47M
Total operating expenses 9.55M 8.41M 5.82M 4.74M 4.54M
Cost of revenue 2.35M 2.06M 0.81M 0.84M 0.81M
Total other income expense net 2.45M 1.94M 1.64M 1.57M -0.02706M
Discontinued operations - - - - -
Net income from continuing ops -6.23431M -4.97296M -2.85966M -1.74377M -2.08027M
Net income applicable to common shares -6.17657M -4.97296M -2.85966M -1.74377M -2.08027M
Preferred stock and other adjustments - - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 10.88M 10.08M 5.40M 8.60M 5.55M
Intangible assets 0.00101M 0.00101M 0.00101M 0.00101M 0.00101M
Earning assets - - - - -
Other current assets 0.12M 1.97M 1.73M 1.30M 1.33M
Total liab 1.63M 1.75M 2.00M 0.99M 1.12M
Total stockholder equity 9.41M 8.38M 3.39M 7.61M 4.44M
Deferred long term liab - - - - -
Other current liab 0.50M 0.55M 1.18M 0.30M 0.44M
Common stock 36.81M 30.18M 19.34M 19.10M 13.39M
Capital stock 36.81M 30.18M 19.34M 19.10M 13.39M
Retained earnings -29.67104M -23.62758M -17.63007M -12.65711M -10.00774M
Other liab - - 0.30M 0.21M 0.43M
Good will - - - - -
Other assets 0.00000M 0.06M 0.06M 0.00000M 0.00000M
Cash 6.64M 6.03M 2.11M 5.60M 2.37M
Cash and equivalents - 5.79M 1.00M 5.05M 0.05M
Total current liabilities 0.90M 1.10M 1.70M 0.78M 0.62M
Current deferred revenue 0.25M 0.37M 0.36M 0.27M -0.06380M
Net debt -6.32385M -5.96323M -2.11151M -5.53579M -2.23218M
Short term debt 0.10M 0.03M -0.35598M 0.07M 0.06M
Short long term debt - - - - -
Short long term debt total 0.32M 0.06M 0.06M 0.07M 0.13M
Other stockholder equity - -6.55268M -1.71084M -6.43812M -3.38380M
Property plant equipment - 1.69M 0.97M 1.26M 1.44M
Total current assets 9.16M 8.33M 4.36M 7.34M 4.12M
Long term investments - - - - -
Net tangible assets - - 3.39M 7.61M 4.44M
Short term investments - - - - -
Net receivables 2.41M 0.21M 0.44M 0.30M 0.36M
Long term debt - - - - -
Inventory - 0.12M 0.08M 0.13M 0.06M
Accounts payable 0.06M 0.15M 0.52M 0.14M 0.18M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 2.27M 1.83M 1.68M 1.17M 1.05M
Additional paid in capital - - - - -
Common stock total equity - - - - 13.39M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -0.00000M 0.06M 0.06M -1.26180M -1.43711M
Deferred long term asset charges - - - - -
Non current assets total 1.71M 1.75M 1.03M 1.26M 1.44M
Capital lease obligations 0.32M 0.06M - 0.07M 0.13M
Long term debt total - 0.03M 0.00000M 0.00000M 0.07M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -1.16513M -0.12946M -0.19100M -1.58613M 0.93M
Change to liabilities 0.00000M 1.01M -0.14885M 0.61M -0.08707M
Total cashflows from investing activities -1.16513M -0.12946M -0.19100M -1.58613M 0.89M
Net borrowings - -0.06905M -0.06380M -0.16492M -0.14750M
Total cash from financing activities 10.77M 0.18M 5.64M 2.82M -0.02875M
Change to operating activities - -0.36195M 0.04M 0.04M 0.87M
Net income -6.17657M -4.97296M -2.85966M -1.74377M -2.08027M
Change in cash 3.92M -3.49332M 3.24M 0.85M -0.80535M
Begin period cash flow 2.11M 5.60M 2.37M 1.51M 2.32M
End period cash flow 6.03M 2.11M 5.60M 2.37M 1.51M
Total cash from operating activities -5.69291M -3.53996M -2.20907M -0.38451M -1.66701M
Issuance of capital stock 10.84M 0.25M 5.70M 3.05M 0.12M
Depreciation 0.53M 0.42M 0.37M 0.36M 0.19M
Other cashflows from investing activities 0.05M 0.00000M 0.01M -0.12782M -0.12782M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables 0.29M -0.13908M 0.06M 0.14M 0.10M
Sale purchase of stock 10.84M 0.25M 5.70M 3.05M 0.12M
Other cashflows from financing activities -0.06551M -0.06905M -0.06380M -0.06880M 0.89M
Change to netincome 0.32M 0.51M 0.32M 0.21M -0.65696M
Capital expenditures 1.22M 0.13M 0.21M 1.59M 0.04M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.29M -0.13908M 0.06M 0.14M 0.13M
Stock based compensation 0.32M 0.51M 0.33M 0.15M -
Other non cash items -0.04587M 1.02M 0.28M 1.00M 1.89M
Free cash flow -6.91082M -3.66942M -2.41424M -1.97064M -0.03799M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
PIQ
Proteomics Intl Labs Ltd		 -0.015 2.31% 0.64 - - 26.79 9.46 92.76 -19.4827
CSL
CSL Ltd		 -3.45 1.22% 278.79 32.86 33.00 9.11 5.02 6.65 20.64
TLX
Telix Pharmaceuticals Ltd		 -0.07 0.27% 25.67 161.73 75.19 12.58 19.98 12.52 109.28
MSB
Mesoblast Ltd		 1.07 54.04% 3.05 - 454.55 312.43 2.49 67.90 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.36 2.79% 12.54 13.51 35.21 8.91 5.13 6.48 8.45

Reports Covered

Stock Research & News

View All

Profile

Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and South East Asia. It provides PromarkerD, a protein-based diagnostic blood test to predict diabetic kidney disease (DKD). The company's products under development include PromarkerEndo, which has completed clinical validation phase for endometriosis diagnosis; PromarkerEso, that has completed clinical validation trials for esophageal cancer diagnosis; and OxiDx (2-tag), which has completed clinical validation phase for oxidative stress treatment. It is also developing diagnostic tests for that includes DKD - T1D, that is under clinical phase for diabetic kidney disease in type 1 diabetes; Asthma and COPD, which has completed proof-of-concept study trials for asthma and chronic obstructive pulmonary disease; Plant Dieback, that is under development phase for phytophthora dieback; Diabetic Retinopathy, which has completed discovery phase for sight-threatening retinopathy; Diabetic Neuropathy, that is under research phase to investigate predictive biomarkers for diabetic neuropathy; and Giardia, a causing gastroenteritis. The company also offers analytical services, such as pharmacokinetic testing, biomarker discovery, protein analysis, project consultation, and specialist contract research. Proteomics International Laboratories Ltd was founded in 2001 and is headquartered in Perth, Australia.

Proteomics Intl Labs Ltd

QEII Medical Centre, Perth, WA, Australia, 6009

Key Executives

Name Title Year Born
Dr. Richard John Lipscombe M.A., MA (Oxford), Ph.D., Ph.D., (London) Co-Founder, MD & Director NA
Ms. Jacqueline Gray Chief Financial Officer NA
Mr. Vikesh Malik Chief Commercialisation Officer NA
Mr. John Chuck Morrison Head of Bus. Devel. NA
Dr. Scott Bringans Head of Research NA
Dr. Pearl Tan Head of Logistics NA
Dr. Kirsten Peters Head of Clinical Studies NA
Ms. Karen Teresa Logan B.Com., FCIS, BCom, DipAppCorpGov, FFin, ACIS, AGI Company Sec. NA
Mr. John Chuck Morrison Head of Business Development NA
Ms. Karen Teresa Logan ACIS, B.Com., BCom, DipAppCorpGov, F Fin, FCIS, FC Company Secretary NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.